

For Immediate Release

**Diabetic Ulcer Rate Cut by 79% in Year Long
Neuropathy Study using Anodyne® Therapy**

TAMPA, FL – August 4, 2004 - Anodyne® Therapy, LLC today announced the publication of a fifth peer-reviewed clinical study demonstrating restoration of sensation in the feet of patients with peripheral neuropathy. The purpose of the study was to measure improvements in net health outcomes after sensation had been restored and patients continued using Anodyne Therapy at home for 12 months. The study appears in the July/August 2004 issue of ***Advances in Skin and Wound Care***.

Previous studies have shown that sensory impairments due to peripheral neuropathy present a significant independent risk for wounds that could not be adequately addressed because of the lack of a treatment intervention for the underlying peripheral neuropathy. Prior to receiving Anodyne treatments, the patients with peripheral neuropathy in this study had sensory loss based on standardized testing using a Semmes-Weinstein monofilament. After obtaining improved foot sensation through the use of Anodyne clinical treatments, all patients received an Anodyne Therapy Home System and continued using it for 12 months. The incidence of diabetic ulcers in the elderly diabetic population is typically 7.2% - 11.6% per year as shown in three separate studies. The incidence of ulcers in this study was 1.5% - a 79% incidence reduction. In addition, 11 of 13 (85%) ulcers in the study population took longer than 8 weeks to heal prior to use of Anodyne. In the year of Anodyne Therapy use, both ulcers that occurred healed within 8 weeks.

“We are thrilled with the publication of this additional study, especially in light of the potential for improved health outcomes through reduced incidence and healing times of diabetic ulcers,” said Craig Turtzo, CEO. “This is our first study to show the benefits of long term use of Anodyne Therapy.” Added Mr. Turtzo, “It is very gratifying to be able to improve the lives of patients with peripheral neuropathy who, prior to Anodyne, did not have access to viable treatment options for their condition. Additionally, it appears that we can help drive down the medical costs normally associated with peripheral neuropathy, which have been estimated to exceed \$37 billion per year among people with diabetes alone.”

Anodyne Therapy treatments are currently available nationwide at more than 1500 outpatient therapy facilities, hospitals, nursing homes, physician offices and home health agencies to improve functional outcomes for patients suffering from peripheral neuropathy, chronic pain and a broad range of other health problems. Products are also available for convenient home use. For more information, visit **www.anodynetherapy.com**.

CONTACT INFORMATION: Kim Stebbings, Vice President, Sales and Marketing
Anodyne Therapy, LLC, 13570 Wright Circle, Tampa, FL 33626
Office: 813-342-4432 ext. 122 Cell: 720-560-0533 Email: kimstebbing@aol.com